Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | TAS2R14 | Q9NYV8 | 3/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | SORT1 | Q99523 | 3/20 | 0.44 |
| ▸ | DHODH | Q02127 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | LIPC | P11150 | 1/20 | 0.41 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.41 |
| ▸ | MPO | P05164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6343631 | 0.86 | MEN1 (0.52) | MEN1KMT2ALMNAPKMGFER | |
| SCHEMBL6345124 | 0.85 | MEN1 (0.56) | MEN1KMT2ALMNAPKMGFER | |
| SCHEMBL6340206 | 0.85 | GFER (0.62) | MEN1KMT2ALMNAPKMGFER | |
| SCHEMBL6341582 | 0.83 | KMT2A (0.56) | MEN1KMT2ALMNAPKMGFER | |
| SCHEMBL6341254 | 0.83 | KMT2A (0.48) | MEN1KMT2ALMNAPKMGFER | |
| SCHEMBL6341693 | 0.83 | GFER (0.63) | MEN1KMT2ALMNAPKMGFER | |
| SCHEMBL6344686 | 0.81 | KMT2A (0.53) | MEN1KMT2ALMNAPKMGFER | |
| SCHEMBL6339758 | 0.81 | MAPT (0.64) | MEN1KMT2ALMNAPKMGFER | |
| SCHEMBL6343392 | 0.81 | KMT2A (0.61) | MEN1KMT2ALMNAPKMGFER | |
| SCHEMBL6344753 | 0.80 | KMT2A (0.53) | MEN1KMT2ALMNAPKMGFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6949648-B2 | Condensed pyrazole derivatives, process for producing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-09-27 | — | — | US | disclosed |
| US-20040097539-A1 | To decreases a tissue disorder caused by a compound having cyclooxygenase inhibiting activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-05-20 | — | — | US | disclosed |
| EP-1380296-A1 | HSP INDUCTOR | Takeda Chemical Industries, Ltd. (JP) | 2004-01-14 | — | — | EP | disclosed |
| US-20030187014-A1 | Condensed pyrazole derivatives, process for producing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-10-02 | — | — | US | disclosed |
| EP-1270572-A1 | CONDENSED PYRAZOLE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097539-A1 | To decreases a tissue disorder caused by a compound having cyclooxygenase inhibiting activity | HSPB1, HSPA1B, HSP90AB1 | MEN1 4642/4885KMT2A 4423/4885LMNA 2421/4885 |
| US-20030187014-A1 | Condensed pyrazole derivatives, process for producing the same and use thereof | PTGS1, PTGIS, IL5 | MEN1 4422/4885KMT2A 3347/4885LMNA 4847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.